Accepted for Publication: June 16, 2021.
Published: August 31, 2021. doi:10.1001/jamanetworkopen.2021.22255
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Shavit R et al. JAMA Network Open.
Corresponding Author: Nancy Agmon-Levin, MD, Clinical Immunology, Angioedema and Allergy Unit, Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer Hospital, Ramat-Gan 52621, Israel (nancy.agmon-levin@sheba.health.gov.il).
Author Contributions: Dr Agmon-Levin had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Shavit, Offengenden, Machnes Maayan, Deutch, Elbaz, Rahav, Levy, Belkin, Regev-Yochay, Afek, Agmon-Levin.
Acquisition, analysis, or interpretation of data: Shavit, Maoz-Segal, Iancovici-Kidon, Offengenden, Haj Yahia, Machnes Maayan, Lifshitz-Tunitsky, Niznik, Frizinsky, Genaim, Rahav, Belkin, Regev-Yochay, Agmon-Levin.
Drafting of the manuscript: Shavit, Maoz-Segal, Offengenden, Haj Yahia, Machnes Maayan, Niznik, Frizinsky, Genaim, Rahav, Levy, Agmon-Levin.
Critical revision of the manuscript for important intellectual content: Shavit, Iancovici-Kidon, Offengenden, Lifshitz-Tunitsky, Frizinsky, Deutch, Elbaz, Rahav, Belkin, Regev-Yochay, Afek, Agmon-Levin.
Statistical analysis: Shavit, Maoz-Segal, Iancovici-Kidon, Haj Yahia, Niznik, Agmon-Levin.
Obtained funding: Agmon-Levin.
Administrative, technical, or material support: Shavit, Maoz-Segal, Offengenden, Haj Yahia, Machnes Maayan, Lifshitz-Tunitsky, Deutch, Elbaz, Belkin, Agmon-Levin.
Supervision: Frizinsky, Genaim, Rahav, Levy, Belkin, Afek, Agmon-Levin.
Conflict of Interest Disclosures: Dr Regev-Yochay reported receiving personal fees from Teva and grants from Pfizer outside the submitted work. No other disclosures were reported.
Funding/Support: This study was supported by the Sheba Fund for Health Services and Research (Registered Association).
Role of the Funder/Sponsor: The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank the infectious diseases and infection prevention and control unit team for operating the COVID-19 referral center, and specifically Vered Roa, BA, Infection Prevention & and Control Unit, Sheba Medical Center; she was not compensated for her contribution.
1.US Food and Drug Administration. Fact sheet for healthcare providers administering vaccine (vaccination providers) emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). Accessed February 27, 2021.
https://www.fda.gov/media/144413/download 5.CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine—United States, December 14-23, 2020.
MMWR Morb Mortal Wkly Rep. 2021;70(2):46-51. doi:
10.15585/mmwr.mm7002e1
PubMedGoogle ScholarCrossref 6.CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine—United States, December 21, 2020-January 10, 2021.
MMWR Morb Mortal Wkly Rep. 2021;70(4):125-129. doi:
10.15585/mmwr.mm7004e1
PubMedGoogle ScholarCrossref